The majority of the ACE2 ASOs remained efficacious in blocking SARS-CoV-2 infection by the B.1.1.7 variant when tested in iAEC2 cells, while select Gapmers targeting the SARS-CoV-2 genome also inhibited infection of iAEC2 cells (Fig 4A). Here, ACE2 is linked to infection.